SUSHRUT - A MAGAZINE OF PHARMACEUTICAL SCIENCES

"Sushrut" is a bimonthly magazine, published by the Institute of Pharmaceutical Sciences, RKDF University, Ranchi. It was first published in August 2024. The theme of the first published magazine was: "Alzheimer's Research & Treatment" The theme of the second edition will be "How AI can improve health for everyone, everywhere"

The articles can be submitted by anyone like Faculty members or they can be students.

You can submit your article before 30th Sept 2024 for the second edition on the below mail ID: pharmacy@rkdfuniversity.org

For any queries feel free to contact no. 8001343454.

Sushrut First published in August 2024

Articles of the First Edition: 

Sr. No.	Title
01	Article 1: Pharmacological Intervention of Alzheimer's Disease
02	Article 2: Pathological Progression of Alzheimer's Disease
03	Article 3: Pharmacogenomics in Alzheimer's Disease-related Dementia Treatment
04	Article 4: Biomarkers for Alzheimer’s Disease
05	Article 5: What Happens to the Brain in Alzheimer's Disease?
06	Article 6: Blood Test Shows Promise for Alzheimer’s Diagnosis
07	Article 7: Sleep Disturbances by Alzheimer's Disease

Pharmacological Intervention of Alzheimer Disease

➧ 
August, 2024 ➧ A MAGAZINE OF PHARMACEUTICAL SCIENCES ➧ ¹Department of Pharmaceutical Sciences, Usha Martin University, Ranchi, Jharkhand-835103, India ➧ Volume 1

Several prescription drugs are approved by the U.S. Food and Drug Administration (FDA) for Alzheimer’s disease to help either manage the symptoms of or to treat the disease. Most FDA-approved drugs work best for people in the early or middle stages of Alzheimer’s. There are currently no known interventions that will cure Alzheimer’s. Alzheimer’s researchers continue to explore a variety of innovative approaches to treat symptoms as well as underlying disease processes. In ongoing clinical trials, they are developing and testing several new possible interventions. These include additional immunotherapy and other drug therapies, cognitive training, diet, and physical activity. While our era offers much more in the way of therapeutics for AD, it is clear that more work still needs to be done.. Read More

: Alzheimer’s disease, Dementia, Pharmacologic Therapy

Pathological Progression of Alzheimer Disease

➧ 
August, 2024 ➧ A MAGAZINE OF PHARMACEUTICAL SCIENCES ➧ ¹Department of Pharmaceutical Sciences, Jharkhand Rai University, Ranchi, Jharkhand-834010, India ➧ Volume 1

According to Centers for Disease Control and Prevention (CDC) data, Alzheimer disease (AD) is ranked as the seventh leading cause of death in the United States in 2022, while COVID-19 ranked fourth. Before the COVID-19 pandemic, AD was the sixth leading cause of death following stroke. AD is characterized pathologically by an accumulation of abnormal neuritic plaques and neurofibrillary tangles in the brain. These pathological changes are accompanied by a loss of neurons, particularly cholinergic neurons in the basal forebrain and the neocortex. Alzheimer's disease tends to develop slowly and gradually worsens over several years.. Read More

: Alzheimer disease, Brain, Plaques, Complex Disorders

Pharmacogenomics in Alzheimer's Disease-related Dementia Treatment

➧ 
August, 2024 ➧ A MAGAZINE OF PHARMACEUTICAL SCIENCES ➧ ¹Department of Pharmaceutical Sciences, Jharkhand Rai University, Ranchi, Jharkhand, 834010, India ➧ Volume 1

The development of pharmacogenomics as an interdisciplinary large-scale systematic approach has been reinforced by the introduction of genomic techniques, such as genotyping, gene sequencing, gene expression, genetic epidemiology, transcriptomics, proteomics, metabolomics and bioinformatics, and other multiplex assay technologies, which allow deeper assessment of disease mechanisms, potential drug targets and metabolism, or associated pathway components. The incorporation of pharmacogenomic protocols to Alzheimer's disease (AD) research and clinical practice can foster therapeutics optimization by helping to develop cost-effective pharmaceuticals and improving drug efficacy and safety.. Read More

: Alzheimer disease, Pharmacogenomic, Genetic Research

Biomarkers for Alzheimer’s disease

➧  ,
August, 2024 ➧ A MAGAZINE OF PHARMACEUTICAL SCIENCES ➧ ¹ Department of Pharmaceutical Sciences, Jharkhand Rai University, Ranchi, Jharkhand, 834010, India, ➧ ² Department of Pharmacy, Ranchi Collage of Pharmacy, Jharkhand 834003, India ➧ Volume 1

The search for meaningful biomarkers is one of the hottest areas of Alzheimer research. These biomarkers should be specific, suitable for routine use in clinical practice, and indicate specific stages of the disease. The emergence of novel biomarkers, such specific microRNA populations, downstream molecules associated with Amyloid-β (Aβ) and tau toxicity, and ultrasensitive detection of seeding-competent Aβ and tau populations are currently being explored for use as early, low-invasive, sensitive, and specific diagnostic probes. Currently under development, seeding aggregation assays are extremely sensitive techniques that exploit the functional properties of Aβ oligomers to seed the polymerization of monomeric Aβ. Recent advances in such innovative techniques may result in a blood-based diagnostic test for Alzheimer disease. Forthcoming research will reveal whether the coveted diagnostic test for Alzheimer disease is a real possibility.. Read More

: Alzheimer Research, Biomarkers, Amyloid-β

What Happens to the Brain in Alzheimer's Disease?

➧ 
August, 2024 ➧ A MAGAZINE OF PHARMACEUTICAL SCIENCES ➧ ¹ Institute of Pharmaceutical Sciences, RKDF University, Ranchi, Jharkhand-834004, India ➧ Volume 1

Alzheimer's disrupts processes vital to neurons and their networks, including communication, metabolism, and repair. It's characterized by changes in the brain that lead to deposits of certain proteins. At first, Alzheimer's usually damages the connections among neurons in parts of the brain involved in memory, including the entorhinal cortex and hippocampus. Damage to nerve cells in the brain can also make it difficult for the person to express thoughts and perform routine tasks without assistance. Alzheimer's disease causes the brain to shrink and brain cells to eventually die. The person in the final months of Alzheimer's disease will experience increased mental and physical deterioration, eventually needing 24-hour care.. Read More

: Alzheimer, Alzheimer’s Disease, Entorhinal cortex, Hippocampus

Blood Test Shows Promise for Alzheimer’s Diagnosis

➧ 
August, 2024 ➧ A MAGAZINE OF PHARMACEUTICAL SCIENCES ➧ ¹ Institute of Pharmaceutical Sciences, RKDF University, Ranchi, Jharkhand-834004, India ➧ Volume 1

Alzheimer's disease is the most common type of dementia. It is a progressive disease beginning with mild memory loss and possibly leading to loss of the ability to carry on a conversation and respond to the environment. A simple blood test shows promise as a way to detect Alzheimer’s disease, which could drastically improve the accuracy and speed of diagnoses. Currently, Alzheimer’s is diagnosed via a mixture of memory and cognitive tests, as well as brain imaging and lab tests. While some blood tests have shown promise as a diagnostic tool, they are hindered by their complexity. A simple blood test has been shown to detect Alzheimer’s disease in routine health care settings with up to 90% accuracy, according to Swedish researchers. The findings were presented at the Alzheimer’s Association International Conference in Philadelphia. The findings could speed the quest for an affordable and accessible way to diagnose patients with memory problems.. Read More

: Alzheimer's disease, Alzheimer’s diagnosis, Blood test

Sleep Disturbances by Alzheimer's Disease

➧ 
August, 2024 ➧ A MAGAZINE OF PHARMACEUTICAL SCIENCES ➧ ¹ Institute of Pharmaceutical Sciences, RKDF University, Ranchi, Jharkhand-834004, India ➧ Volume 1

Sleep disturbances, as well as sleep-wake rhythm disturbances, are typical symptoms of Alzheimer's disease (AD) that may precede the other clinical signs of this neurodegenerative disease. Typical disturbances of the neurophysiological sleep architecture in the course of the AD include deep sleep and paradoxical sleep deprivation. Factors that might contribute to sleep disturbances and sundowning include mental and physical exhaustion at the end of the day. Many people with Alzheimer's wake up more often and stay awake longer during the night. It is quite common for a person, especially in the later stages, to spend a lot of their time sleeping both during the day and night. This can sometimes be distressing for the person's family and friends, as they may worry that something is wrong... Read More

: Alzheimer's disease, Sleep disturbances, Insomania

You can download this file for free for all students and faculty. This is attached below.

Download PDF